Medicare Enrolled
Dr. Veerpal Singh, MBBS,M.D.
Hematology & Oncology · Elgin, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Singh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Singh?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Singh
Dr. Veerpal Singh is a hematology & oncology specialist in Elgin, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Singh performed 253,186 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Singh received a total of $12,084 from 76 pharmaceutical and/or device companies across 476 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Singh is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 1% volume in IL
$12,084 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗253,186
Medicare services
Top 1% in IL for hematology & oncology
Not available
Unique patients (not deduplicated)
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
49,200 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
37,500 | $0 | $6 |
| Nivolumab injection (Opdivo) | 32,280 | $24 | $76 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
21,100 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 20,200 | $43 | $137 |
| Denosumab injection (Prolia/Xgeva) | 17,040 | $18 | $67 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
12,110 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
9,620 | $6 | $28 |
| Bevacizumab-bvzr biosimilar injection, 10 mg An injection of bevacizumab-bvzr, a biosimilar medication, administered in a 10 mg dose. |
7,260 | $23 | $155 |
| Anti-nausea injection (Aloxi/palonosetron) | 4,710 | $1 | $114 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
3,990 | $4 | $116 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
3,380 | $34 | $235 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
3,004 | $8 | $35 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,625 | $8 | $19 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
2,550 | $21 | $181 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
2,102 | $12 | $105 |
| Anti-nausea injection (ondansetron/Zofran) | 1,788 | $0 | $3 |
| Rituximab injection, 10 mg Administration of a 10 mg dose of rituximab medication via injection. |
1,780 | $64 | $237 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,761 | $95 | $231 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,758 | $69 | $168 |
| Injection, leucovorin calcium, per 50 mg | 1,495 | $3 | $25 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,094 | $2 | $13 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
1,032 | $86 | $1,348 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
968 | $11 | $93 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
932 | $23 | $152 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
897 | $103 | $686 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
775 | $1 | $9 |
| Iron dextran injection, 50 mg An injection containing 50 mg of iron dextran administered to the patient. |
724 | $13 | $43 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
660 | $91 | $824 |
| Etoposide chemotherapy injection Administration of etoposide, a chemotherapy medication, via injection. The dose specified is 10 mg. |
652 | $1 | $10 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
633 | $2 | $300 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
626 | $63 | $157 |
| Gemcitabine chemotherapy injection, 200 mg An injection of gemcitabine hydrochloride, a chemotherapy medication, administered in a 200 mg dose. |
588 | $3 | $28 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
577 | $51 | $304 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
517 | $1 | $7 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
422 | $10 | $73 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
414 | $1 | $6 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
396 | $16 | $91 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 323 | $3 | $373 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
317 | $51 | $334 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
298 | $22 | $156 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
262 | $2 | $19 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
256 | $1 | $17 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 239 | $14 | $35 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
216 | $43 | $105 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
199 | $16 | $97 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
196 | $4 | $29 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
191 | $4 | $25 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
188 | $71 | $70 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
187 | $7 | $431 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
139 | $26 | $249 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
139 | $55 | $205 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
122 | $44 | $281 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
111 | $73 | $485 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
110 | $104 | $297 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
101 | $206 | $1,726 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
84 | $15 | $108 |
| New patient office visit, complex (60-74 min) | 64 | $173 | $432 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
61 | $128 | $344 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
42 | $6 | $33 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
41 | $1 | $19 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
31 | $96 | $232 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
29 | $6 | $62 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
25 | $139 | $412 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
21 | $50 | $135 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
18 | $144 | $324 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
16 | $136 | $523 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.8% high complexity
92.5% medium
4.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,084
Total received (2018-2024)
Avg $1,726/year across 7 years
Top 28% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
76
Companies
476
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,788
2023
$2,600
2022
$2,207
2021
$1,256
2020
$446
2019
$1,193
2018
$594
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$1,423
PFIZER INC.
$311
AstraZeneca Pharmaceuticals LP
$209
Tempus AI, Inc
$183
Daiichi Sankyo Inc.
$180
ABBVIE INC.
$174
Octapharma USA, Inc.
$148
Celgene Corporation
$147
Astellas Pharma US Inc
$89
Merck Sharp & Dohme LLC
$88
Gilead Sciences, Inc.
$70
TerSera Therapeutics LLC
$69
ARRAY BIOPHARMA INC
$69
JAZZ PHARMACEUTICALS INC.
$68
GlaxoSmithKline, LLC.
$55
Agios Pharmaceuticals, Inc.
$52
Alexion Pharmaceuticals, Inc.
$41
E.R. Squibb & Sons, L.L.C.
$38
Takeda Pharmaceuticals U.S.A., Inc.
$33
Dendreon Pharmaceuticals LLC
$31
Celltrion USA Inc.
$30
Aveo Pharmaceuticals, Inc.
$30
Incyte Corporation
$29
Janssen Pharmaceuticals, Inc
$28
GE HEALTHCARE
$27
Immunocore Limited
$25
BeiGene USA, Inc.
$24
Biocon Biologics Inc
$24
Pharmacosmos Therapeutics Inc.
$22
ADC Therapeutics America, Inc.
$19
Adaptive Biotechnologies Corporation
$19
PUMA BIOTECHNOLOGY, INC.
$19
Genentech USA, Inc.
$18
Top 3 companies account for 51.3% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$2,648
AstraZeneca Pharmaceuticals LP
$726
Janssen Pharmaceuticals, Inc
$714
Genentech USA, Inc.
$593
PFIZER INC.
$570
Merck Sharp & Dohme LLC
$429
Takeda Pharmaceuticals U.S.A., Inc.
$315
Amgen Inc.
$297
Daiichi Sankyo Inc.
$276
Celgene Corporation
$268
E.R. Squibb & Sons, L.L.C.
$257
ABBVIE INC.
$257
NOVARTIS PHARMACEUTICALS CORPORATION
$250
Gilead Sciences, Inc.
$233
Astellas Pharma US Inc
$223
JAZZ PHARMACEUTICALS INC.
$221
Merck Sharp & Dohme Corporation
$190
Tempus AI, Inc
$183
Inari Medical, Inc.
$158
Blueprint Medicines Corporation
$150
Octapharma USA, Inc.
$148
GlaxoSmithKline, LLC.
$145
TerSera Therapeutics LLC
$142
Incyte Corporation
$142
ARRAY BIOPHARMA INC
$118
Pharmacyclics LLC, An AbbVie Company
$113
Regeneron Healthcare Solutions, Inc.
$112
MorphoSys, US Inc.
$105
EMD Serono, Inc.
$104
Janssen Products, LP
$100
Boehringer Ingelheim Pharmaceuticals, Inc.
$98
Agios Pharmaceuticals, Inc.
$96
G1 Therapeutics, Inc.
$93
Alexion Pharmaceuticals, Inc.
$90
GENZYME CORPORATION
$87
CTI BioPharma Corp.
$85
Lilly USA, LLC
$80
Exelixis Inc.
$80
Adaptive Biotechnologies Corporation
$75
Seagen Inc.
$72
Dendreon Pharmaceuticals LLC
$70
Karyopharm Therapeutics Inc.
$55
ADC Therapeutics America, Inc.
$53
Novo Nordisk Inc
$47
Biocon Biologics Inc
$47
Puma Biotechnology, Inc.
$44
Eisai Inc.
$42
Pharmacosmos Therapeutics Inc.
$42
Clovis Oncology, Inc.
$38
Pharmacyclics LLC, an AbbVie Company
$32
Kite Pharma, Inc.
$32
Celltrion USA Inc.
$30
Deciphera Pharmaceuticals Inc.
$30
Aveo Pharmaceuticals, Inc.
$30
GE HEALTHCARE
$27
AMAG Pharmaceuticals, Inc.
$27
Alnylam Pharmaceuticals Inc.
$25
Blue Earth Diagnostics Limited
$25
Immunocore Limited
$25
Janssen Biotech, Inc.
$25
BeiGene USA, Inc.
$24
SERVIER PHARMACEUTICALS LLC
$22
Bayer HealthCare Pharmaceuticals Inc.
$21
Organon LLC
$21
AbbVie Inc.
$20
Bayer Healthcare Pharmaceuticals Inc.
$20
Myriad Genetic Laboratories, Inc.
$20
Acerta Pharma LLC
$19
PUMA BIOTECHNOLOGY, INC.
$19
AbbVie, Inc.
$17
Mylan Institutional Inc.
$17
Dova Pharmaceuticals
$16
Bio Products Laboratory USA, Inc.
$16
Verastem, Inc.
$16
Fortovia Therapeutics, Inc.
$15
Taiho Oncology, Inc.
$15
Top 3 companies account for 33.8% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Aliqopa · Avastin · Axumin · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CALQUENCE · CERDELGA · COSELA · CREON · CYRAMZA · Cabometyx · Columvi · Copiktra · Cresemba · Doptelet · ELIQUIS · ELREXFIO · EMEND · ENHERTU · EPKINLY · Enhertu · Erleada · FERAHEME · FLOWTRIEVER CATHETER · FOTIVDA · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · GIVLAARI · Gammaplex · Hulio · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INQOVI · IRESSA · Imbruvica · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Neulasta · Novoeight · Nplate · Nubeqa · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · Ogivri · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · ROZLYTREK · S · SCEMBLIX · Soltamox · TAGRISSO · TASIGNA · TECENTRIQ · TEPMETKO · TIBSOVO · TIVDAK · TUKYSA · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VEGZELMA · VENCLEXTA · VOTRIENT · Venclexta · Vonjo · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex · clonoSEQ · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
95
County median income
$100,678
Nearest hospital to ZIP centroid (approximate)
ADVOCATE SHERMAN HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Singh is a mixed practice specialist, with above-average Medicare volume (top 1% in IL), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Singh experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Singh performed 49,200 iron sucrose injection (venofer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Singh receive payments from pharmaceutical companies?
Yes. Dr. Singh received a total of $12,084 from 76 companies across 476 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Singh's costs compare to other hematology & oncology specialists in Elgin?
Dr. Singh's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Singh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Elgin
Browse hematology & oncology specialists in Elgin ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology